Lumos Pharma, Inc. (LUMO)
| Market Cap | 175.81M |
| Revenue (ttm) | 561,000 |
| Net Income (ttm) | -12.17M |
| Shares Out | 8.29M |
| EPS (ttm) | -2.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $21.19 |
| Previous Close | $22.13 |
| Change ($) | -0.94 |
| Change (%) | -4.25% |
| Day's Open | 21.94 |
| Day's Range | 21.11 - 22.01 |
| Day's Volume | 10,182 |
| 52-Week Range | 0.89 - 35.91 |
Lumos Pharma (LUMO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumo s Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the com...
AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the comp...
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2020 Results - Earnings Call Transcript
AUSTIN, Texas, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial re...
Lumos (LUMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the comp...
AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the ...
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q2 2020 Results - Earnings Call Transcript
AUSTIN, Texas, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial r...
AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it ...
AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced tha...
As of late, it has definitely been a great time to be an investor in Lumos Pharma.
About LUMO
Lumos Pharma, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharm... [Read more...]
| Industry Biotechnology | Founded 2011 |
| CEO Richard J. Hawkins | Employees 28 |
| Stock Exchange NASDAQ | Ticker Symbol LUMO |
Financial Performance
In 2019, Lumos Pharma's revenue was $936,000, a decrease of -92.50% compared to the previous year's $12.47 million. Losses were -$42.99 million, -19.79% less than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for Lumos Pharma stock is "Buy." The 12-month stock price forecast is 33.00, which is an increase of 55.73% from the latest price.